Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 2014-2017

  Stark, Klaus ^a,c   Günther, Matthias ^a   Neuhaus, Ruth ^a   Reinke, Petra ^a   Schröder, Karsten ^b   Linnig, Stefan ^a   Bienzle, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Centre for Hemodialysis   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS A; HUMAN; IMMUNOGENICITY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION;

EID: 0032712249     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315125     Document Type: Article

References (14)

1. 1. Bell BP, Shapiro CN, Alter MJ, et al. The diverse patterns of hepatitis A epidemiology in the United States - implications for vaccination strategies. J Infect Dis 1998;178:1579-84.
2. 2. Termorshuizen F, van de Laar MJW. Upsurge of hepatitis A in the Netherlands - early 1998. Eurosurveillance 1998;3:110-2.
3. 3. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201-5.
4. 4. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
5. 5. Cendoroglo-Neto M, Draibe SA, Silva AE, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients. Nephrol Dial Transplant 1995;10:240-6.
6. 6. Corcoran GD, Brink NS, Millar CG, et al. Hepatitis C virus infection in haemodialysis patients: a clinical and virological study. J Infect 1994;28: 279-85.
7. 7. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994;44:446-51.
8. 8. Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22:295-302.
9. 9. Huzly D, Neifer S, Reinke P, et al. Routine immunizations in adult renal transplant recipients. Transplantation 1997;63:839-45.
10. 10. Burbach G, Bienzle U, Stark K, et al. Influenza vaccination in liver transplant recipients. Transplantation 1999;67:753-5.
11. 11. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus infected and uninfected homosexual men. J Infect Dis 1997;176:1064-7.
12. 12. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998;27:881-5.
13. 13. Fujiyama S, Odoh K, Tanaka M, Kuramoto I, Tomita K. Evaluation of the timing of the booster injection after a primary vaccination against hepatitis A. J Gastroenterol Hepatol 1997;12:172-5.
14. 14. Weimer R, Zipperle S, Daniel V, Pomer S, Staehler G, Opelz G. IL-6 independent monocyte/B cell defect in renal transplant recipients with long-term stable graft function. Transplantation 1994;57:54-9.